Key result
Pirfenidone decreases viability and downregulates fibrotic markers in LPS-induced fibroblasts by counteracting miR-21-5p.
Why the study?
Treatment options for acquired tracheal stenosis are limited, and the effect of pirfenidone on miR-21-5p and its biological function had not been clarified.
Does pirfenidone inhibit fibroblast proliferation in LPS-induced fibroblasts by targeting miR-21-5p?
Does pirfenidone inhibit fibroblast proliferation in LPS-induced fibroblasts by targeting miR-21-5p?
Pirfenidone inhibits fibroblast proliferation and fibrotic marker expression in an in vitro model of acquired tracheal stenosis, likely via the miR-21-5p/Smad7 pathway.
May inhibit fibroblast proliferation via miR-21-5p/Smad7 in vitro; leaves open clinical translation in tracheal stenosis.
OBJECTIVE: Treatment options for acquired tracheal stenosis (ATS) are limited due to a series of pathophysiological changes including inflammation and cell proliferation. Micro ribonucleic acid-21-5p (miR-21-5p) may promote the excessive proliferation of fibroblasts. However, various types of fibrosis can be prevented with pirfenidone (PFD). Currently, the effect of PFD on miR-21-5p and its biological function has not been clarified. In this study, PFD was evaluated as a potential treatment for ATS by inducing fibroblast proliferation in lipopolysaccharide (LPS)-induced fibroblasts by targeting miR-21-5p. METHODS: For 48 h, 1 g/ml LPS was used to generate fibroblasts in vitro, followed by the separation of cells into four groups: control, PFD, mimic, and mimic + PFD. The Cell Counting Kit-8 (CCK-8) technique was adopted to measure the proliferation of fibroblasts. Real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot (WB) were used to measure the relative expressions of tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), drosophila mothers against decapentaplegic 7 (Smad7) and collagen type I alpha 1(COL1A1) messenger RNA (mRNA) and proteins, respectively. RESULTS: (1) At 0, 24, 48, and 72 h, fibroblast growth was assessed using the CCK-8 method. Compared with the control group, the mimic group showed the highest fibroblast viability, and the PFD group showed the lowest fibroblast viability. However, fibroblast viability increased in the mimic + PFD group but decreased in the mimic one. (2) RT-qPCR and WB showed that the mimic group exhibited a significant up-regulation in the relative expressions of TNF-α, TGF-β1, and COL1A1 mRNA and proteins but a down-regulation in the relative expression of Smad7 mRNA and protein compared with the control one. In the PFD group, the results were the opposite. Nevertheless, the relative expressions of TNF-α, TGF-β1, and COL1A1 mRNA and proteins were increased, whereas that of Smad7 mRNA was decreased in the mimic + PFD group. The change was less in the mimic group. CONCLUSION: PFD may have a preventive and curative effect on ATS by inhibiting fibroblast proliferation and the fibrotic process and possibly through down-regulating miR-21-5p and up-regulating Smad7 and its mediated fibrotic and inflammatory responses.
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied Acquired tracheal stenosis. Pirfenidone vs. Control, mimic, and mimic + PFD groups was evaluated on Fibroblast viability and relative expressions of TNF-α, TGF-β1, Smad7, and COL1A1. Pirfenidone decreased fibroblast viability and down-regulated TNF-α, TGF-β1, and COL1A1 while up-regulating Smad7, counteracting the effects of miR-21-5p mimic in LPS-induced fibroblasts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: